Clinical Drug Investigation

, Volume 11, Issue 2, pp 77–83 | Cite as

A Double-Blind Controlled Trial of the Efficacy and Safety of Taurohyodeoxycholic Acid in the Treatment of Dyspeptic Disturbances Associated with Gallstones or Other Hepatic Disorders

  • P. Ventura
  • M. Girola
  • R. Germogli
Clinical Use


In a controlled, randomised, parallel-group, double-blind trial the efficacy and safety of taurohyodeoxycholic acid (THDCA) was compared with another commonly used biliary acid, ursodeoxycholic acid (UDCA), in 100 patients with pain or other dyspeptic disturbances associated with hepatic or biliary disorders. THDCA and the reference drug were administered at 250mg doses twice a day for 2 months. The disturbances evaluated were: right hypochondrium pain, epigastric pain, nausea or vomiting, belching, epigastric bloating, flatulence or meteorism, lipid intolerance, constipation or diarrhoea. The degree of severity of the disturbances was recorded using an arbitrary 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe), and the total score was calculated as the sum. Dyspeptic symptoms were reduced or completely disappeared in 87.2% of patients treated with THDCA (80.4% in the UDCA-treated group). Statistical analysis (Wilcoxon’s test with a test power higher than 80%) revealed significant differences between the reduction of symptoms obtained in the 2 groups (total score from 8.38 to 2.74 in the THDCA group and from 7.83 to 4.09 in the UDCA group). Adverse effects were reported in only a few patients (4.3% in the THDCA group and 8.7% in the UDCA group), without any statistically significant difference between the 2 groups. On the basis of the clinical evidence, and with a good level of statistical confidence, THDCA can be considered useful in the treatment of dyspeptic disturbances associated with gallstones or other hepatic disorders.


Bile Acid Primary Biliary Cirrhosis Drug Invest Ursodeoxycholic Acid Dyspeptic Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Leiss O, Bosch T, Von Bergman K. Effects of bile acid feeding on lipoprotein concentration, change in cholesterol synthesis and biliary lipid secretion in patients with radiolucent gallstones. In: Paumgartner G, Stiehl A, Gerok W, editors. Bile acids and lipids, London; MTP Press, 1981: 247Google Scholar
  2. 2.
    Nilsell K, Angelin B, Leijd B, et al. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology 1993; 85: 1248Google Scholar
  3. 3.
    Maton PM, Murphy GM, Dowling RH. Ursodeoxycholic treatment of gallstones. Lancet 1977; 2: 1297PubMedCrossRefGoogle Scholar
  4. 4.
    Stiehl A, Czygan P, Kommereell B, et al. Ursodeoxycholic versus chenodeoxycholic acid: comparison of their effects on bile acid and bile lipid composition in patients with cholesterol gallstones. Gastroenterology 1978; 75: 1016PubMedGoogle Scholar
  5. 5.
    Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis: a review. Dig Dis Sci 1982; 27: 737PubMedCrossRefGoogle Scholar
  6. 6.
    Nakagawa S, Makino I, Ishizaki T, et al. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 1977; 2: 367PubMedCrossRefGoogle Scholar
  7. 7.
    Attili AF, Angelico M, Cantafora A, et al. Bile acid induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 1986; 19: 57PubMedCrossRefGoogle Scholar
  8. 8.
    Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993; 104: 1865PubMedGoogle Scholar
  9. 9.
    Leuschner U, Leuschner M, Sierratzi J, et al. Gallstones dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30: 642PubMedCrossRefGoogle Scholar
  10. 10.
    Poupon R, Poupon RE, Calmus J, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834PubMedCrossRefGoogle Scholar
  11. 11.
    De Caestecker JS, Jazrawi RP, Petroni ML, et al. Ursodeoxycholic acid in chronic liver disease. Gut 1991; 32: 1061PubMedCrossRefGoogle Scholar
  12. 12.
    Price WH. Gallbladder dyspepsia. BMJ 1963; 2: 138PubMedCrossRefGoogle Scholar
  13. 13.
    Inter-Hospital Clinical Research Group. Effect of ursodeoxycholic acid on dyspepsia in patients with gallstones or other biliary tract anomalies. Curr Ther Res 1979; 26: 230Google Scholar
  14. 14.
    Frigerio G. Ursodeoxycholic acid in the treatment of dyspepsia: report of a multicenter controlled trial. Curr Ther Res 1979; 26: 214Google Scholar
  15. 15.
    Laurenzi F, Polazzi A, Benci A, et al. Uso dell’acido ursodesossicolico nella dispepsia nel gastroresecato. Atti e memorie delia Società Medica delia Provincia di Roma. Anno V; no. 3 (1): 1979Google Scholar
  16. 16.
    Bianchini L. L’impiego dell’acido ursodesossicolico in pazienti affetti da patologia dispeptico-biliare. Riv Pat Clin 1984; 39: 371Google Scholar
  17. 17.
    Aggio L, Mastropolo G, DiMario F, et al. Impiego dell’acido ursodessocolico nella dispepsia funzionale. Min Diet Gastroenterol 1986; 32: 1Google Scholar
  18. 18.
    Colombo P, Cherie-Lignière EL, Palmieri B, et al. Ulteriore contributo alla terapia della dispepsia biliare. Arch Med Int 1987; 39: 75Google Scholar
  19. 19.
    Vlahcevic ZR, Prug MF, Gregory DH. Bile acids in parenchymal liver cell diseases. Clin Gastroenterol 1977; 6: 25PubMedGoogle Scholar
  20. 20.
    Bianchini E, Forzani F, Contos S, et al. L’impiego dell’acido tauroursodesossicolico in pazienti affetti da patologia dispeptico-biliare. Riv Pat Clin 1984; 34: 371Google Scholar
  21. 21.
    Del Vecchio Blanco C, Caporaso N, Gentile S, et al. Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: a double blind controlled trial. J Int Med Res 1982; 10: 278PubMedGoogle Scholar
  22. 22.
    Realini S, Reiner M, Frigerio G. Le traitement des troubles dyspeptiques, de la lithiase et de la dyscinesie biliares avec l’acide ursodesoxycholique. Schweiz Med Wochenschr 1980; 110: 879PubMedGoogle Scholar
  23. 23.
    Angelico M, Avella A. Nuovi sali biliari naturali all’orizzonte nella terapia medica della calcolosi biliare: prospettiva di impiego dell’acido tauroiodesossicolico. Epat 1988; 34: 151Google Scholar
  24. 24.
    De Bernardi M, Contos S, Feletti F, et al. Studio sulla tossicita’ peri-postnatale nel ratto e determinazione della DL50 di un farmaco a base di acido tauroiodesossicolico in confronto al-l’acido tauroursodesossicolico. Acta Tox Farm 1989; 10: 57Google Scholar
  25. 25.
    Malvisi J, Molteni R, Anfossi P, et al. Farmacodinamica dell’acido tauroiodesossicolico nel ratto e nel topo: effetti sulla lipemia, sulla colesterolemia, sulla calcolosi col-esterolica e sulla steatosi da dieta ipercolesterolica. Acta Tox Farm 1990; 11: 205Google Scholar
  26. 26.
    Mpalatsos B, Xourgias B. Medical therapy with bile acids of biliary dyspepsia and associated hepatopathies. Acta Tox Farm 1991; 12: 157Google Scholar
  27. 27.
    Gandin C, Mogavero L, Baiocchi L, et al. Taurohyodeoxycholic acid dissolves human cholesterol gallstones faster than other taurine conjugates. Int J Gastroenterol 1991; 23: 305Google Scholar
  28. 28.
    Sacquet E, Parquet M, Riottot M, et al. Intestinal absorption, excretion, and biotransformation of hyodeoxycholic acid in man. J Lipid Res 1983; 24: 604PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • P. Ventura
    • 1
  • M. Girola
    • 1
  • R. Germogli
    • 2
  1. 1.Medicine DivisionCivil HospitalBergamoItaly
  2. 2.Research DivisionDR Drug Research SrlMilanItaly

Personalised recommendations